Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Binder

Showing results (51-60 of 95) with videos related to

Pageof 10
Sort By:
Blood Advances|November 13, 2024
Retreatment of multiple myeloma with previously refractory drugsUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Pageof 10

Showing results (51-60 of 95) with videos related to

Sort By:
Pageof 10
Blood Advances|November 13, 2024
Retreatment of multiple myeloma with previously refractory drugsUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
Blood Advances|March 2, 2022
Utility of PET/CT in assessing early treatment response in patients with newly diagnosed multiple myelomaCharalampos Charalampous, Utkarsh Goel, Stephen M Broski, et al.
American Journal of Hematology|June 8, 2026
Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL AmyloidosisMaximilian J Steinhardt, Ute Hegenbart, Tamer Hellou, et al.
Blood Cancer Journal|March 27, 2024
Outcomes of patients with multiple myeloma refractory to standard dose vs low dose lenalidomideUtkarsh Goel, Charalampos Charalampous, Prashant Kapoor, et al.
American Journal of Hematology|July 8, 2023
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myelomaSaurabh Zanwar, Matthew Ho, Yi Lin, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Research Square|April 17, 2026
Risk of AL Amyloidosis is Associated with Degree of Free Light Chain Elevation and Duration of ExposureAngela Dispenzieri, Maximilian Steinhardt, Eli Muchtar, et al.
American Journal of Hematology|April 17, 2018
Time to plateau as a predictor of survival in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Blood Cancer Journal|December 12, 2023
Muscle and fat composition in patients with newly diagnosed multiple myelomaNadine H Abdallah, Hiroki Nagayama, Naoki Takahashi, et al.
Blood Advances|August 21, 2023
Outcomes of patients with primary refractory multiple myeloma in the era of triplet and quadruplet induction therapyCharalampos Charalampous, Utkarsh Goel, Prashant Kapoor, et al.
Pageof 10